Stock ANVS ANNOVIS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 12:13:31 2024-04-29 pm EDT 		5-day change 1st Jan Change
7.87 USD -56.30% Intraday chart for Annovis Bio, Inc. -42.78% -64.84%
04:20pm Annovis Bio reports positive results in mid-stage Alzheimer's treatment trial RE
Apr. 01 Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 51.96 142.4 109.6 191.9 198.3 - -
Enterprise Value (EV) 1 51.96 142.4 109.6 186.1 93.11 144.5 100.2
P/E ratio -8.67 x -9.25 x -4.33 x -3 x -6.47 x -6.23 x -7.07 x
Yield - - - - - - -
Capitalization / Revenue - - - - - - 24.2 x
EV / Revenue - - - - - - 12.2 x
EV / EBITDA - - - -4.13 x -2.49 x -3.28 x -1.57 x
EV / FCF - - - -4.66 x -2.91 x -2.81 x -1.8 x
FCF Yield - - - -21.5% -34.4% -35.6% -55.6%
Price to Book - - - -21.8 x 4.1 x 9.24 x 5 x
Nbr of stocks (in thousands) 6,892 8,101 8,164 10,262 11,011 - -
Reference price 2 7.540 17.58 13.43 18.70 18.01 18.01 18.01
Announcement Date 3/3/21 3/2/22 3/31/23 3/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - 8.209
EBITDA 1 - - - -45.04 -37.4 -44 -64
EBIT 1 - -14.54 -25.51 -45.04 -31.4 -55.34 -63.53
Operating Margin - - - - - - -773.93%
Earnings before Tax (EBT) 1 - -14.49 -25.33 -56.2 -33.97 -58.56 -80.91
Net income 1 -5.462 -14.49 -25.33 -56.2 -33.97 -58.56 -80.91
Net margin - - - - - - -985.6%
EPS 2 -0.8700 -1.900 -3.100 -6.230 -2.782 -2.892 -2.547
Free Cash Flow 1 - - - -39.97 -32 -51.4 -55.7
FCF margin - - - - - - -678.52%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 3/3/21 3/2/22 3/31/23 3/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - - - - - - - - - - -
EBITDA 1 - - - - - - - - - -10.44 -6.4 -6.7 -11.9 -12.4 -
EBIT 1 -2.854 -5.92 -5.914 -8.754 -7.674 -3.169 -9.97 -9.76 -14.86 -10.44 -7.5 -6.65 -8.75 -8.5 -
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -2.848 -5.915 -5.894 -8.718 -7.621 -3.095 -9.737 -9.537 -14.72 -22.21 -8.487 -7.5 -9.023 -8.923 -
Net income 1 -2.848 -5.915 -5.894 -8.7 -7.621 -3.095 -9.737 -9.537 -14.72 -22.21 -8.487 -7.5 -9.023 -8.923 -
Net margin - - - - - - - - - - - - - - -
EPS 2 -0.3500 -0.7500 -0.7200 -1.070 -0.9300 -0.3800 -1.190 -1.070 -1.630 -2.330 -0.7767 -0.5833 -0.6333 -0.6167 -0.4800
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/3/21 3/2/22 5/4/22 8/8/22 11/8/22 3/31/23 5/10/23 8/14/23 11/8/23 3/29/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - - - 5.75 105 53.8 98.1
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - - - -40 -32 -51.4 -55.7
ROE (net income / shareholders' equity) - - - - -110% -77.8% -105%
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 - - - -0.8600 4.390 1.950 3.600
Cash Flow per Share 2 - - - -4.430 -1.790 -2.450 -2.290
Capex 1 - - - - 1 2 2
Capex / Sales - - - - - - 24.36%
Announcement Date 3/3/21 3/2/22 3/31/23 3/29/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
18.01 USD
Average target price
35.4 USD
Spread / Average Target
+96.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ANNOVIS BIO, INC. Stock Annovis Bio, Inc.
-40.05% 198M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.64% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.36% 95.28B
ARGENX SE Stock argenx SE
+1.75% 22.15B
BIONTECH SE Stock BioNTech SE
-15.56% 21.02B
GENMAB A/S Stock Genmab A/S
-8.42% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.43% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.80% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.75% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ANVS Stock
  4. Financials Annovis Bio, Inc.